Condition: Platinum-resistant Ovarian Cancer · Sponsor: Stemline Therapeutics, Inc.
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
This description comes directly from the study's public registry record.
Stemline Trials · 1-877-332-7961 · cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists & Research Institute | Sarasota, Florida, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| Icon Cancer Centre | South Brisbane, Queensland, Australia | Recruiting |
| Cancer Research SA | Aberfoyle Park, Australia | Recruiting |
| Hospital Universitario Dexeus - Grupo Quironsalud | Barcelona, Spain | Recruiting |
| Clínica Universidad Navarra | Madrid, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07226427